These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38934860)

  • 1. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Ladefoged B; Pedersen AD; Seefeldt J; Nielsen BRR; Eiskjær H; Lichscheidt E; Clemmensen T; Gillmore JD; Poulsen SH
    J Am Heart Assoc; 2024 Jul; 13(13):e034213. PubMed ID: 38934860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis.
    Clemmensen TS; Mølgaard H; Sörensen J; Eiskjaer H; Andersen NF; Mellemkjaer S; Andersen MJ; Tolbod LP; Harms HJ; Poulsen SH
    Eur J Heart Fail; 2017 Nov; 19(11):1457-1465. PubMed ID: 28836315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
    Rosenbaum AN; AbouEzzeddine OF; Grogan M; Dispenzieri A; Kushwaha S; Clavell A; Daly RC; Edwards BS
    Transplantation; 2018 Nov; 102(11):1909-1913. PubMed ID: 29677073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy.
    Iino T; Nagao M; Tanaka H; Yoshikawa S; Asakura J; Nishimori M; Shinohara M; Harada A; Watanabe S; Ishida T; Hirata KI; Toh R
    Sci Rep; 2024 Sep; 14(1):20508. PubMed ID: 39227655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse correlation between age of onset and myocardial amyloid deposition quantified by
    Kanaya H; Shiraishi S; Ogasawara K; Iwashita K; Sakamoto F; Takashio S; Mikami Y; Tsujita K; Hirai T
    Ann Nucl Med; 2024 Sep; 38(9):744-753. PubMed ID: 38874878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
    Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
    Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restrictive cardiac phenotype as primary cause of impaired aerobic capacity in Afro-Caribbean patients with val122ile variant transthyretin amyloid cardiomyopathy.
    Monfort A; Banydeen R; Demoniere F; Courty B; Codiat R; Neviere R; Inamo J
    Amyloid; 2020 Sep; 27(3):145-152. PubMed ID: 32024385
    [No Abstract]   [Full Text] [Related]  

  • 15. DPD Quantification Correlates With Extracellular Volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis.
    Rettl R; Calabretta R; Duca F; Kronberger C; Binder C; Willixhofer R; Poledniczek M; Hofer F; Doná C; Beitzke D; Loewe C; Nitsche C; Hengstenberg C; Badr Eslam R; Kastner J; Bergler-Klein J; Hacker M; Kammerlander AA
    JACC Adv; 2024 Oct; 3(10):101261. PubMed ID: 39309666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure.
    Parovic M; Okwose NC; Bailey K; Velicki L; Fras Z; Seferovic PM; MacGowan GA; Jakovljevic DG
    ESC Heart Fail; 2019 Apr; 6(2):449-454. PubMed ID: 30788904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
    Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
    Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ
    J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.